epigenetics
The company aims to release an initial tissue-based prognostic this year, with a less-invasive sponge-sampling version for screening high-risk individuals to follow in 2023.
Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium
New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.
Genomic Answers for Kids Team Releases Thousands of Genomes to Gain Insights Into Rare Diseases
Premium
The Children's Mercy Research Institute is using exome sequencing, genome sequencing, and other methods to diagnose and study rare pediatric conditions in underserved patients.
Burning Rock Details Plans for Cancer Monitoring Assay, Adds New Data Supporting Early Detection
Premium
Both the MRD test, BR Prophet, and a six-cancer screening assay, BR Predict, are slated for launch in China next year, initially for contracted hospital customers.
Oxford BioDynamics Awarded Grant to Apply EpiSwitch to ICI Cancer Therapy Response
The two-year PACT grant will fund the application of the EpiSwitch technology to the analysis of primary and acquired ICI resistance in several clinical trials.